Aurinia Pharmaceuticals (AUPH) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.28
- Estimate
- $0.24
- Surprise
- +16.7%
- Revenue (period 2026-06-30)
- $83.2M
- Score today
- 6.1/10
Revenue source: xbrl.
How the report landed
Aurinia Pharmaceuticals (AUPH) beat the $0.24 estimate with adjusted EPS of $0.28 — a large 16.7% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates AUPH Buy (Wait) at 6.1/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +16.7% surprise compares with a +163.5% four-quarter average. Next scheduled report: 2027-03-01.
What supports the rating
- Strong earnings beat streak (4/4)
- High-quality business
What argues against it
- Cyclical risk: PE expanding 2.0x (earnings normalizing)
- Thin upside margin: 4.0%
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $15.48
- Entry target
- $14.32
- Price target
- $16.09
- Stop
- $13.32
- Upside to target
- +3.9%
- Reward-to-risk
- 0.5:1
Forward estimates sit below the trailing run-rate (13.6× forward vs 6.9× trailing) — consensus expects earnings to decline from here.
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
AUPH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.11B
- P/E (fwd)
- 13.6
- P/E (ttm)
- 6.9
- 52-week range
- $13.52–$19.25
- Off 52-week high
- 19.6%
- RSI (14)
- 31
- Volume vs avg
- 1.00×
- Score today
- 6.1/10